Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anidulafungin.

David Murdoch1, Greg L Plosker

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|October 1, 2004
PubMed
Summary
This summary is machine-generated.

Anidulafungin, an echinocandin antifungal, effectively treats esophageal candidiasis by inhibiting fungal cell-wall synthesis. It demonstrated comparable efficacy to fluconazole with good tolerability in clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Direct access CT coronary angiography in patients referred with suspected cardiac chest pain: a novel patient pathway.

Open heart·2026
Same author

The importance of microbiology reference laboratories and adequate funding for infectious disease surveillance.

The Lancet. Digital health·2024
Same author

Optimising Cardiology Ambulatory Care Pathways: A Comprehensive Approach to Admission Avoidance and Timely Intervention in a Post-Pandemic Healthcare Landscape.

Acute medicine·2024
Same author

Impact of Cannabis Use on Immune Cell Populations and the Viral Reservoir in People With HIV on Suppressive Antiretroviral Therapy.

The Journal of infectious diseases·2023
Same author

Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium.

The Lancet. Digital health·2023
Same author

Preventing Recurrent Cardioembolic Stroke: Right Approach, Right Patient (PRECISE) Study Protocol.

Cerebrovascular diseases (Basel, Switzerland)·2022
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Anidulafungin is a novel echinocandin antifungal agent.
  • It targets beta-(1,3)-D-glucan synthase, disrupting fungal cell-wall synthesis.
  • It exhibits broad-spectrum activity against Candida and Aspergillus species, including resistant strains.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of anidulafungin in patients with esophageal candidiasis.
  • To compare anidulafungin with fluconazole for treating this condition.

Main Methods:

  • A large, multicenter, double-blind, randomized trial was conducted.
  • Patients received intravenous anidulafungin (50 mg/day) or oral fluconazole (100 mg/day) for 2-3 weeks.
  • Both groups received a loading dose on day 1.

Related Experiment Videos

Main Results:

  • Anidulafungin was as effective as fluconazole in achieving endoscopic cure, clinical success, and microbiological success at the end of treatment.
  • Adverse events were generally mild and not dose- or infusion-related.
  • Common adverse events included phlebitis, headache, nausea, vomiting, and pyrexia.

Conclusions:

  • Anidulafungin is an effective and well-tolerated alternative for treating esophageal candidiasis.
  • Its mechanism of action and efficacy against resistant strains make it a valuable antifungal agent.